Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 5:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 5,242 matching trials from the live ClinicalTrials.gov search.
Conditions
Craniopharyngioma, Child
Interventions
Tumor and Blood Specimens
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Days to 21 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
Biological · Drug
Lead sponsor
Toray Industries, Inc
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more
Conditions
Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung Carcinoma, Uveal Melanoma, Hepatocellular Carcinoma, Glioma, Sarcomatoid Carcinoma
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Trametinib, Uprosertib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • New York, New York • Nashville, Tennessee + 1 more
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
oblimersen sodium, docetaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
New York, New York
Conditions
Glioma, High Grade Glioma, Pontine Tumors
Interventions
Dasatinib, Everolimus
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
1 Year to 50 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Malignant Gliomas, Oligodendrogliomas, Astrocytomas
Interventions
3 Tesla scanning
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Glioma, Brain Tumor, Glioblastoma Multiforme, GBM, Gliosarcoma, GS
Interventions
lapatinib ditosylate, Adjuvant therapy, Conventional surgery, Neoadjuvant therapy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
gefitinib, pharmacological study, laboratory biomarker analysis, questionnaire administration, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer
Interventions
RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
10
States / cities
Palo Alto, California • West Haven, Connecticut • South Bend, Indiana + 7 more
Conditions
Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas
Interventions
Sunitinib, Everolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Solid Tumor, Adult, Solid Tumor Cancer
Interventions
DF6215, pembrolizumab, KEYTRUDA®
Drug
Lead sponsor
Dragonfly Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Diego, California + 5 more
Conditions
Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Interventions
arsenic trioxide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
16 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
94
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
Conditions
Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, Kidney Cancer, Liver Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Sarcoma
Interventions
colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study, conventional surgery
Biological · Other · Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Conditions
Precancerous Condition, Stage 0 Melanoma, Stage I Melanoma, Stage II Melanoma
Interventions
lovastatin, placebo, biopsy, laboratory biomarker analysis
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Orange, California • Tampa, Florida • Salt Lake City, Utah
Conditions
Cancer
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2015
U.S. locations
1
States / cities
Duarte, California
Conditions
Glioblastoma Multiforme
Interventions
CAR.B7-H3T cells infusion
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Breast Cancer, Lung Cancer, Melanoma (Skin)
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Timeline
2021 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Completed Phase 2 Interventional Results available

A Study in Recurrent Glioblastoma (GB)

NCT01582269
Conditions
Glioblastoma
Interventions
Galunisertib, Lomustine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
5
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 2 more
Conditions
Non-small Cell Lung Cancer, Glioblastoma Multiforme
Interventions
GLR2007
Drug
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Lafayette, Indiana • Omaha, Nebraska • Philadelphia, Pennsylvania + 1 more
Conditions
Diffuse Intrinsic Pontine Glioma, PNET, Ependymoma, Germinoma, Medulloblastoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month to 21 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Melanoma, Skin Cancer
Interventions
autologous anti-MART-1 F5 T-cell receptor, Cyclophosphamide, Fludarabine, Aldesleukin, autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Islet Cell Carcinoma, Neuroendocrine Carcinoma, Neuroendocrine Tumor, Pancreatic Neoplasms
Interventions
Everolimus 10 mg, Octreotide Depot
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
Conditions
Adult Brain Tumors
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
Michael Prados
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Francisco, California